Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 4/20 | 0.68 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.68 |
| ▸ | BRAF | P15056 | 2/20 | 0.66 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.55 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.55 |
| ▸ | NAMPT | P43490 | 5/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | CSF1R | P07333 | 1/20 | 0.52 |
| ▸ | PPARG | P37231 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13162335 | 0.90 | BRAF (0.76) | CYP11B2CYP11B1BRAFSGMS2LRRK2 | |
| SCHEMBL8611362 | 0.85 | CYP11B2 (0.67) | CYP11B2CYP11B1BRAFSGMS2LRRK2 | |
| SCHEMBL13162000 | 0.83 | CYP11B2 (0.76) | CYP11B2CYP11B1BRAFLRRK2NAMPT | |
| SCHEMBL21056024 | 0.82 | PPARG (0.72) | CYP11B2CYP11B1BRAFSGMS2CSF1R | |
| SCHEMBL13162545 | 0.82 | CYP11B2 (0.64) | CYP11B2CYP11B1BRAFSGMS2LRRK2 | |
| SCHEMBL21056019 | 0.82 | GRM5 (0.67) | CYP11B2CYP11B1BRAFSGMS2LRRK2 | |
| SCHEMBL13162002 | 0.81 | CYP11B2 (1.00) | CYP11B2CYP11B1BRAFSGMS2NAMPT | |
| SCHEMBL13161988 | 0.81 | CYP11B2 (0.72) | CYP11B2CYP11B1BRAFSGMS2LRRK2 | |
| SCHEMBL3487444 | 0.81 | CYP11B2 (0.72) | CYP11B2CYP11B1BRAFNAMPTNPC1 | |
| SCHEMBL13638956 | 0.81 | CYP11B2 (0.62) | CYP11B2CYP11B1BRAFSGMS2LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2456435-B1 | HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE | UNIV LELAND STANFORD JUNIOR (US) | 2015-06-24 | — | — | EP | disclosed |
| EP-2206707-B1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2014-07-23 | — | — | EP | disclosed |
| US-8304547-B2 | Azolecarboxamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2012-11-06 | — | — | US | disclosed |
| US-8304547-B2 | Azolecarboxamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2012-11-06 | — | — | US | disclosed |
| US-20120225862-A1 | HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE | AUCKLAND UNIVSERVICES LIMITED (NZ) | 2012-09-06 | — | — | US | disclosed |
| US-20100249088-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225862-A1 | HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE | BRDT, NISCH, PAICS | CYP11B2 862/4885CYP11B1 1543/4885BRAF 567/4885 |
| US-20100249088-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | TRPV1, FGFR3, GPR17 | CYP11B2 2221/4885CYP11B1 2489/4885BRAF 1984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.